2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $0 | -$25M | — | — | -$19M | $21M | $17M |
| 2023 | $300000 | -$37M | -335.3% | -9314.0% | -$26M | $38M | $1M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $0 | -$7M | — | — | -$4M | $23M | $13M |
| Dec '25 | $0 | -$3M | — | — | -$4M | $21M | $17M |
| Sep '25 | $0 | -$10M | — | — | -$4M | $21M | $5M |
| Jun '25 | — | -$4M | — | — | -$5M | $17M | $8M |
| Mar '25 | $0 | -$8M | — | — | -$8M | $18M | $13M |
| Dec '24 | $137000 | -$57M | -1011.7% | -42375.9% | -$8M | $17M | $21M |
| Sep '24 | $132000 | $4M | -213.6% | -3352.3% | -$7M | $14M | $28M |
| Jun '24 | $254000 | -$6M | -168.5% | -2621.7% | -$7M | — | — |
| Mar '24 | $26000 | -$8M | -1984.6% | -33903.8% | -$7M | — | — |
| Dec '23 | $78000 | -$9M | -328.2% | -6837.2% | -$7M | $38M | $1M |
| Sep '23 | $41000 | -$11M | -517.1% | -22148.8% | — | — | — |
How the market has priced ADGM against its own fundamentals since 2024-08 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
See the revenue and net-income charts above for Adagio Medical Holdings, Inc.'s multi-year trend.
As of FY2025, Adagio Medical Holdings, Inc. reported $21M of total debt against $17M of cash; operating income covered interest expense -7.5×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.